Use of daclizumab in the immunosuppression of high-risk kidney and kidney/pancreas recipients: Warsaw Transplantation Center experience.
Baczkowska
T
T
Transplantation Institute, Medical University of Warsaw, 59 Nowogrodzka Street, 02-006 Warsaw, Poland.
Kukula
K
K
Nowacka-Cieciura
E
E
Cieciura
T
T
Lewandowska
D
D
Ciecierski
R
R
Grochowiecki
T
T
Rowinski
W
W
Szmidt
J
J
Durlik
M
M
Lao
M
M
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016035:Pancreas Transplantation / Q000276:immunology*; D011044:Poland; D006435:Renal Dialysis / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab